(Q44384918)

2 December 2017

title

Mutagenic outcome of combined antiviral drug treatment during human immunodeficiency virus type 1 replication (English)

1 reference

2 December 2017

Louis M Mansky

1

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

2 December 2017

1 reference

2 December 2017

volume

307

1 reference

2 December 2017

issue

1

1 reference

2 December 2017

page(s)

116-121

1 reference

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900069-7

7 January 2021

Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900069-7

7 January 2021

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900069-7

7 January 2021

Genetic drift and within-host metapopulation dynamics of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900069-7

7 January 2021

Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900069-7

7 January 2021

Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900069-7

7 January 2021

Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900069-7

7 January 2021

Forward mutation rate of human immunodeficiency virus type 1 in a T lymphoid cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900069-7

7 January 2021

3'-Azido-3'-deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900069-7

7 January 2021

Virus mutators and antimutators: roles in evolution, pathogenesis and emergence

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900069-7

7 January 2021

Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900069-7

7 January 2021

The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900069-7

7 January 2021

Reverse transcriptase fidelity and HIV-1 variation

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900069-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900069-7

1 reference

7 January 2021

The antiretrovirus drug 3'-azido-3'-deoxythymidine increases the retrovirus mutation rate

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900069-7

7 January 2021

Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900069-7

7 January 2021

Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900069-7

7 January 2021

10.1016/S0042-6822(02)00069-7

Identifiers

DOI

1 reference

2 December 2017

1 reference